Ratings Opthea Limited

Equities

OPT

AU000000OPT2

Market Closed - Australian S.E. Other stock markets 02:10:16 2024-05-07 am EDT			5-day change	1st Jan Change
0.65 ^AUD	0.00%		+4.84%	+14.04%

Apr. 03	Opthea Limited Announces Board Changes	CI
Feb. 29	Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OPTHEA LIMITED	+14.04%	285M	C-
MODERNA, INC.	+22.81%	46.81B	B-
LONZA GROUP AG	+46.73%	41.29B	A
IQVIA HOLDINGS INC.	-1.88%	41.37B	B
CELLTRION, INC.	-6.20%	28.87B	C
ICON PUBLIC LIMITED COMPANY	+11.33%	26.06B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B	B
BIO-TECHNE CORPORATION	-1.43%	11.96B	B+
MEDPACE HOLDINGS, INC.	+30.73%	12.39B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	12.08B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes